Related Experiment Video

Updated: Jul 21, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative

Robert Hsu1, David J Benjamin2, Misako Nagasaka3

  • 1Division of Medical Oncology, Department of Internal Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Cancers
|July 29, 2023
PubMed

Insights

Capmatinib, a targeted therapy, shows efficacy in advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Ongoing research explores combination therapies and strategies to overcome resistance to this MET tyrosine kinase inhibitor.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) remains a significant cause of cancer-related mortality.
  • Dysregulation of the MET proto-oncogene, particularly MET exon 14 skipping mutations and amplification, drives NSCLC progression.
  • MET tyrosine kinase inhibitors (TKIs) represent a targeted therapy approach for NSCLC with MET alterations.

Purpose of the Study:

  • To review the development and clinical application of Capmatinib, a MET TKI, for NSCLC.
  • To discuss the evidence supporting Capmatinib's efficacy in patients with MET exon 14 skipping mutations.
  • To explore future directions, including combination therapies and strategies to overcome resistance.

Main Methods:

  • Narrative review of preclinical and early-phase clinical studies.
  • Analysis of data from the pivotal GEOMETRY mono-1 trial.
  • Examination of ongoing clinical trials investigating Capmatinib in various settings.

Main Results:

  • Capmatinib demonstrated significant efficacy in patients with advanced NSCLC harboring MET exon 14 skipping mutations.
  • FDA approval of Capmatinib, with Foundation One CDx as its companion diagnostic, marked a milestone in NSCLC treatment.
  • Early clinical trials support the investigation of Capmatinib in combination therapies and for acquired resistance mechanisms.

Conclusions:

  • Capmatinib is an effective targeted therapy for NSCLC with MET exon 14 skipping mutations.
  • Future research focuses on optimizing Capmatinib efficacy, managing resistance, and expanding its indications.
  • Combination strategies and novel agents like antibody-drug conjugates hold promise for improving outcomes in NSCLC.
Keywords:
MET dysregulationNSCLCcapmatinibdetectiontyrosine kinase inhibitor

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K